1. Mendez OA, Koshy AA. Toxoplasma gondii: entry, association, and physiological influence on the central nervous system. PLoS Pathog. 2017; 13(7): e1006351. doi: 10.1371/journal.ppat.1006351.
2. Schlüter D, Barragan A. Advances and challenges in understanding cerebral toxoplasmosis. Front Immunol. 2019; 10: 242. doi: 10.3389/fimmu.2019.00242.
3. Megli CJ, Coyne CB. Infections at the maternal-fetal interface: an overview of pathogenesis and defence. Nat Rev Microbiol. 2022; 20(2): 67-82. doi: 10.1038/s41579-021-00610-y.
4. Uddin AHMM, Hossain D, Ahsan MI, et al. Review on diagnosis and molecular characterization of Toxoplasma gondii in humans and animals. Trop Biomed. 2021; 38(4): 511-39. doi: 10.47665/tb.38.4.091.
5. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009; 39(12): 1385-94. doi: 10.1016/j.ijpara.2009.04.003.
6. Tyebji S, Seizova S, Hannan AJ, et al. Toxoplasmosis: a pathway to neuropsychiatric disorders. Neurosci Biobehav Rev. 2019; 96: 72-92. doi: 10.1016/j.neubiorev.2018.11.012.
7. Flegr J. Effects of Toxoplasma on human behavior. Schizophr Bull. 2007; 33(3): 757-60. doi: 10.1093/schbul/sbl074.
8. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012; 25(2): 264-96. doi: 10.1128/CMR.05013-11.
9. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363(9425): 1965-76. doi: 10.1016/S0140-6736(04)16412-X.
10. Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022; 23(1): 3-20. doi: 10.1038/s41580-021-00418-x.
11. Nishi L, Sanfelice RADS, da Silva Bortoleti BT, et al. Moringa oleifera extract promotes apoptosis-like death in Toxoplasma gondii tachyzoites in vitro. Parasitology. 2021; 148(12): 1447-57. doi: 10.1017/S0031182021001086.
12. Yektaeian N, Malekpour A, Atapour A, et al. Genetic immunization against toxoplasmosis: a review article. Microb Pathog. 2021; 155: 104888. doi: 10.1016/j.micpath.2021.104888.
13. Warner RC, Chapman RC, Davis BN, et al. Review of DNA vaccine approaches against the parasite Toxoplasma gondii. J Parasitol. 2021; 107(6): 882-903. doi: 10.1645/20-157.
14. Rezaei F, Sarvi S, Sharif M, et al. A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization. Microb Pathog. 2019; 126: 172-84. doi: 10.1016/j.micpath.2018.11.003.
15. Araujo FG, Remington JS. Partially purified antigen preparations of Toxoplasma gondii protect against lethal infection in mice. Infect Immun. 1984; 45(1): 122-6. doi: 10.1128/iai.45.1.122-126.1984.
16. Krahenbuhl JL, Ruskin J, Remington JS. The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol. 1972; 108(2): 425-31. https://pubmed.ncbi.nlm.nih.gov/5049090/
17. Zorgi NE, Galisteo AJ Jr, Sato MN, et al. Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites. Med Microbiol Immunol. 2016; 205(4): 297-314. doi: 10.1007/s00430-015-0447-5.
18. Brinkmann V, Remington JS, Sharma SD. Protective immunity in toxoplasmosis: correlation between antibody response, brain cyst formation, T-cell activation, and survival in normal and B-cell-deficient mice bearing the H-2k haplotype. Infect Immun. 1987; 55(4): 990-4. doi: 10.1128/iai.55.4.990-994.1987.
19. Reyes L, Frenkel JK. Specific and nonspecific mediation of protective immunity to Toxoplasma gondii. Infect Immun. 1987; 55(4):856-63. doi: 10.1128/iai.55.4.856-863.1987.
20. Rahimi MT, Sarvi S, Sharif M, et al. Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice. Parasitol Res. 2017; 116(2): 609-16. doi: 10.1007/s00436-016-5325-6.
21. Li ZY, Chen J, Petersen E, et al. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine. 2014; 32(25): 3058-65. doi: 10.1016/j.vaccine.2014.03.042.
22. Horner R, Gassner JGMV, Kluge M, et al. Impact of Percoll purification on isolation of primary human hepatocytes. Sci Rep. 2019; 9(1): 6542. doi: 10.1038/s41598-019-43042-8.
23. Léger JL, Pichaud N, Boudreau LH. Purification of functional platelet mitochondria using a discontinuous Percoll gradient. Methods Mol Biol. 2021; 2276: 57-66. doi: 10.1007/978-1-0716-1266-8_4.
24. Li ZY, Lu J, Zhang NZ, et al. Immunization with plasmid DNA expressing heat shock protein 40 confers prophylactic protection against chronic Toxoplasma gondii infection in Kunming mice. Parasite. 2018; 25: 37. doi: 10.1051/parasite/2018040.
25. Innes EA, Bartley PM, Maley S, et al. Veterinary vaccines against Toxoplasma gondii. Mem Inst Oswaldo Cruz. 2009; 104(2): 246-51. doi: 10.1590/s0074-02762009000200018.
26. Zhu Y, Xu Y, Hong L, et al. Immunization with a DNA vaccine encoding the Toxoplasma gondii’s GRA39 prolongs survival and reduce brain cyst formation in a murine model. Front Microbiol. 2021; 12: 630682. doi: 10.3389/fmicb.2021.630682.
27. Falcón J, Freyre A. Toxoplasma gondii: prototype immunization of lambs against formation of muscle and brain cysts. Vet Parasitol. 2009; 166(1-2): 15-20. doi: 10.1016/j.vetpar.2009.08.012.
28. Ducournau C, Moiré N, Carpentier R, et al. Effective nanoparticle-based nasal vaccine against latent and congenital toxoplasmosis in sheep. Front Immunol. 2020; 11: 2183. doi: 10.3389/fimmu.2020.02183.
29. Zulpo DL, Igarashi M, Sammi AS, et al. rROP2 from Toxoplasma gondii as a potential vaccine against oocyst shedding in domestic cats. Rev Bras Parasitol Vet. 2017; 26(1): 67-73. doi: 10.1590/S1984-29612017007.
30. Mévélec MN, Lakhrif Z, Dimier-Poisson I. Key limitations and new insights into the Toxoplasma gondii parasite stage switching for future vaccine development in human, livestock, and cats. Front Cell Infect Microbiol. 2020; 10: 607198. doi: 10.3389/fcimb.2020.607198.
31. Liu E, Van Grol J, Subauste CS. Atg5 but not Atg7 in dendritic cells enhances IL-2 and IFN-γ production by Toxoplasma gondii-reactive CD4+ T cells. Microbes Infect. 2015; 17(4): 275-84. doi: 10.1016/j.micinf.2014.12.008.
32. Passos ST, Silver JS, O'Hara AC, et al. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol. 2010; 184(4): 1776-83. doi: 10.4049/jimmunol.0901843.
33. Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29: 71-109. doi: 10.1146/annurev-immunol-031210-101312.
34. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2): 133-46. doi: 10.1038/nri1001.